

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Original Article

Are high urea values before intravenous immunoglobulin replacement a risk factor for COVID-related mortality?

Running Title: Risk factors for COVID-related mortality?

Gökhan AYTEKİN^{1,*}, Emel ATAYIK¹

¹Department of Immunology and Allergy, Konya City Hospital, Konya, Turkey

***Correspondence:** ayteking@gmail.com

ORCIDs:

Gökhan AYTEKİN: <https://orcid.org/0000-0002-9089-5914>

Emel ATAYIK: <https://orcid.org/0000-0002-7011-7752>

Corresponding Author:

Gokhan AYTEKIN, MD,

University of Health Sciences, Konya City Hospital,

Division of Allergy and Clinical Immunology,

42080, Konya Turkey

Phone: +90 505 533 73 55 **Email:** ayteking@gmail.com

27

28 **Informed consent**

29 The study protocol was approved by the Ethics committee of the Karatay University
30 (with the decision dated 09.02.2021, decision number: 2020/021). Informed consent
31 was obtained from study participants.

32 Manuscripts that have not been presented orally or as a poster.

33 **Funding source:** No funding was secured for the study.

34 **Financial disclosure:** The authors have no financial relationship relevant to this article
35 to disclose.

36 **Conflict of interest:** The authors have no conflicts of interest to disclose.

37 **Acknowledgement:** None

38 **Disclaimers:** None

39 **Abstract word count:** 250

40 **Text word count:** 3097

41

42

43

44

45

46

47

48

49

50 **ORIGINAL ARTICLE**

51 **Title of the manuscript:** Are high urea values before intravenous immunoglobulin
52 replacement a risk factor for COVID-related mortality?

53 **Abstract**

54 **Objective:** Since the World Health Organization accepted The Coronavirus Disease
55 2019 (COVID-19) as a pandemic and there is still no effective treatment, it becomes
56 crucial that the physicians interested in COVID-19 treatment share all the data they
57 acquire, particularly in vulnerable patient groups, to reduce morbidity and mortality.

58 **Methods:** The study included 81 adult (Female: 27, Male: 54) COVID-19 patients who
59 were hospitalized for the treatment of COVID-19 between April 2020 and September
60 2020 and were followed-up, treated and consulted in the immunology clinic for
61 intravenous immunoglobulin (IVIG) treatment.

62 **Results:** The univariate analysis found that the number of days of hospitalization in
63 service, being intubated, number of IVIG treatment days, and the urea value before
64 IVIG treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074,
65 p:0.004, respectively). As a result of multivariate analysis, being intubated and urea
66 value before IVIG treatment were found to be independent risk factors for mortality
67 (p:0.001 and p:0.009).

68 It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity
69 value for mortality in COVID-19 patients was 46.2%, and the specificity was 35.5%
70 (p:0.029)

71 **Conclusion:** The study found that urea values before IVIG treatment were a risk factor
72 for mortality in patients who received IVIG treatment for COVID-19. This is important
73 as it indicates that BUN values should be closely monitored in patients given IVIG

74 treatment for COVID-19. It also suggests that when resources are limited and risk
75 stratification is required in COVID-19 patients, BUN values can be helpful.

76 **Keywords:** SARS-CoV-2, immunoglobulin, mortality, blood urea nitrogen, COVID-19

77 -

78

79 **1. Introduction**

80 The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
81 syndrome coronavirus-2 (Sars-CoV-2), has affected the whole world in economic,
82 social, spiritual, and many other areas, particularly in the field of health, since
83 December 2019, when it was first described (1, 2). As the disease is highly contagious,
84 the virus spread worldwide in a short time and caused one of the most catastrophic
85 pandemics in human history (3). Although there are some vaccines to reduce virus
86 transmission and develop protection against it, it is obvious that vaccinating all the
87 people in the world will not be possible in such short term. Although it has been more
88 than one year since the WHO (World Health Organization) accepted COVID-19 as a
89 pandemic, there is still no effective treatment. Until now, many treatment options,
90 particularly antimalarial drugs and antivirals, systemic corticosteroids, tocilizumab,
91 anakinra, conventional plasma therapy, and intravenous immunoglobulin (IVIG)
92 therapy, have been tried in the form of monotherapy or combinations for treating
93 COVID-19, there is still no consensus on its treatment (4-7).

94

95 For this reason, it becomes crucial that the physicians interested in COVID-19 treatment
96 share all the data they acquire, particularly in vulnerable patient groups, to reduce
97 morbidity and mortality. Regarding COVID-19 treatment management, many countries
98 have created their treatment protocols, and many associations have published guidelines
99 for its treatment. COVID-19 treatment in Turkey has been primarily applied in line with
100 the TC Ministry of Health protocols. In general, the patients positive for SARS-CoV-2
101 Polymerase Chain Reaction (PCR) (+) were put on hydroxychloroquine and favipiravir
102 treatment at appropriate doses. Patients who did not benefit from these treatments

103 and/or had underlying risk factors were hospitalized. In addition to respiratory support
104 treatments, patients were treated with conventional plasma, systemic steroid therapy,
105 immunomodulatory therapies such as tocilizumab and anakinra, and IVIG treatment,
106 whichever appropriate, as line therapies (8). IVIG was administered as per the clinical
107 immunologists' opinions and in the proper dose and time intervals.

108 Considering that pulmonary lesions in COVID-19 are caused by viral infiltrates and
109 inflammatory response, IVIG treatment provides inflammatory cytokine balance,
110 inhibits auto-reactive T cells, reduces antibody production from CD19⁺ B cells, and
111 reduces macrophage activity. The IVIG treatment is thought to provide a regression in
112 pulmonary lesions, reducing the need for mechanical ventilation, length of hospital stay,
113 and mortality rates in these patients (9, 10). Therefore, this study aimed to
114 retrospectively examine the data of patients who reported to the immunology clinic for
115 IVIG treatment in a tertiary referral hospital and who were hospitalized, followed up,
116 and treated for COVID-19. The study also investigated the effects of the patients'
117 clinical, laboratory, and treatment characteristics and risk factors for mortality in
118 patients with COVID-19 treating with IVIG treatment.

119 **2. Methods**

120 **Study design and study population**

121 The study included 81 adult (Female [F]: 27, 33.3%; Male [M]: 54, 66.7%) COVID-19
122 patients who were hospitalized for the treatment of COVID-19 in a tertiary referral
123 hospital between April 2020 and September 2020 and were followed-up, treated and
124 consulted in the immunology clinic for IVIG treatment. A review of medical records
125 (including information on age, sex, disease duration) was undertaken. Venous blood
126 samples for biochemical analyses were drawn after at least ten hours of fasting, early in

127 the morning. All biochemical analyses were conducted in the Central Biochemistry
128 Laboratory of the Konya Education and Research Hospital.

129 Complete blood counts were performed using Sysmex XN-10 (Sysmex Corporation,
130 Kobe, Japan) analyzers with the fluorescent flow cytometry method. Serum creatinine
131 levels were measured using the Jaffe method. Quantitative determination of serum IgG,
132 IgM, IgA, and IgE was done through particle-enhanced immunonephelometry using the
133 Siemens BN II/BN ProSpec system (Erlangen, Germany).

134 The follow-up period of all patients started with their hospitalization. For the patients
135 who died, the number of days between the date of hospitalization and death was
136 accepted as the follow-up period. The duration of follow-up was calculated by
137 confirming whether the discharged patients were alive or not through the TC Death
138 Reporting System 2 weeks after discharge. For patients who died within two weeks of
139 discharge, the follow-up period was accepted as the number of days between the date of
140 hospitalization and death. For patients who lived more than two weeks after discharge,
141 the follow-up period was calculated by adding 14 days to the number of days they
142 stayed in the hospital.

143 The time until hospitalization, resulting from the emergence of SARS-CoV-2-related
144 symptoms such as fever, cough, and body pain, was considered the duration of illness.
145 The duration of the follow-up in the service was specified as the day of hospitalization
146 and the follow-up period in the intensive care unit as the duration of intensive care
147 hospitalization. All patients in the study received IVIG treatment. Some patients were
148 followed only in the service and received IVIG treatment in the service. Some patients
149 received IVIG treatment in the intensive care unit. Patients who received IVIG

150 treatment in the service and those who received IVIG treatment in the first 24/48 h after
151 their admission to intensive care were specified as the IVIG treatment ICU first 24/48 h.

152 The systemic inflammatory index (SII) was calculated by the formula platelet x
153 neutrophil/lymphocyte. The SARS-CoV-2 diagnosis was established with the detection
154 of the SARS-CoV-2 genome via the PCR method from the nasopharyngeal sample
155 (nasal swab) in patients with symptoms suggestive of SARS-CoV-2 infection such as
156 fever, cough, shortness of breath, joint and body pain, and/or viral infiltration on lung
157 imaging (PA chest radiography or lung tomography).

158 The permission for the study was obtained from the Republic of Turkey, Ministry of
159 Health Scientific Research Platform. In addition, an ethics committee approval was
160 obtained from Karatay University Ethics Committee (with the decision dated
161 09.02.2021, decision number: 2020/021). Written informed consent was obtained from
162 each patient. The study was conducted as per the principles of the Declaration of
163 Helsinki.

164 **Statistical Analyses**

165 Statistical analyses were performed using the SPSS version 22.0 software package
166 (IBM Corp., Armonk, NY, USA). Normally distributed parameters were presented as
167 mean \pm standard deviation, and data that were not normally distributed were expressed
168 as median (interquartile range: minimum-maximum). Descriptive data were presented
169 as frequencies and percentages and compared using the Chi-square test. Comparisons
170 between baseline characteristics were performed by independent Student t, Mann-
171 Whitney rank-sum, Fisher's exact or Chi-square tests where appropriate. Independent
172 predictors for mortality were determined using binomial logistic regression analysis,
173 Cox regression analysis, and Kaplan-Meier test. ROC curves are used to choose the

174 most appropriate cut-off for urea level. A *p*-value of <0.05 was considered statistically
175 significant.

176

177 **3. Results**

178 A total of 81 patients, 27 of whom were women (33.3%), were included in the study.

179 The average age of the patients was 71 (26–94) years. During the follow-up, the
180 mortality rate was 64.2%. The rate of intubated patients was 45.7%. The average
181 follow-up period was 19 (1–38) days. The duration of hospitalization was 17 (1–38)
182 days, and the duration of hospitalization in intensive care was 10 (0–30) days. All
183 patients received hydroxychloroquine and favipiravir treatment during their follow-up.

184 In addition, IVIG treatment was given to all patients. While 35 patients (43.2%)
185 received tocilizumab treatment, 15 patients (18.5%) received conventional plasma and
186 33 patients (40.7%) received pulse steroid treatment. 61.7% of the patients in the first
187 24 h of their admission to intensive care, and 64.2% of the patients in the first 48 h of
188 their admission to intensive care received IVIG treatment. The demographic, laboratory,
189 and clinical characteristics of the patients have been summarized in Table 1.

190 There was no statistically significant difference between the patients who died during
191 their follow-up and the patients who survived in terms of age, gender, tocilizumab
192 treatment, conventional plasma treatment, and the number of days of hospitalization in
193 the service. We observed significant differences in terms of intubated patient ratio, pulse
194 steroid therapy, hospitalization white blood cell count, hospitalization platelet count,
195 lymphocyte percentage before IVIG treatment, neutrophil count before IVIG treatment,
196 hospitalization C-reactive protein (CRP) values, CRP levels before IVIG treatment, urea
197 values before IVIG treatment, hospitalization lactate dehydrogenase (LDH) levels,

198 hospitalization systemic inflammatory index (SII) levels, SII levels before IVIG
199 treatment, and NLR (Neutrophil Lymphocyte Ratio) levels before IVIG treatment. The
200 comparison of demographic, laboratory, and clinical characteristics of the patients who
201 died and survived has been summarized in Table 1.

202 The univariate analysis found that the number of days of hospitalization in service,
203 being intubated, number of IVIG treatment days, and the urea value before IVIG
204 treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074,
205 p:0.004, respectively) (Table 2). As a result of multivariate analysis, being intubated
206 and urea value before IVIG treatment were found to be independent risk factors for
207 mortality (p:0.001 and p:0.009, respectively) (Table 3).

208 It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity
209 value for mortality in COVID-19 patients receiving IVIG treatment was 46.2%, and the
210 specificity was 35.5% (p:0.029) (Table 4) (Figure 1).

211

212 **4. Discussion**

213 The SARS-CoV-2 virus has caused one of the most severe pandemics in human history
214 and has put a lot of pressure, particularly on healthcare systems, since March 2020,
215 when it was declared as a pandemic by WHO. The SARS-CoV-2 virus has caused the
216 deaths of approximately 3 million people in nearly one year since its outbreak (2, 11).

217 At present, there is no globally accepted treatment scheme for treating patients
218 hospitalized for COVID-19. Therefore, it is crucial to determine the prognostic factors
219 in vulnerable patient groups and to develop treatment modalities specific to patient
220 groups according to these factors to reduce mortality and morbidity. In line with this
221 opinion, this study found that being intubated and urea values before IVIG treatment are

222 independent risk factors for COVID-19-related mortality in patients hospitalized for
223 COVID-19 and given IVIG treatment.

224 It has been reported that 7% of COVID-19 patients develop acute renal failure (12, 13).

225 In addition, renal failure has been reported to increase COVID-19-related hospital
226 deaths in mortality studies (14-19). Cheng et al. (15) showed an increase in blood urea

227 nitrogen increased mortality 3.97 times in COVID-19 patients. Another study reported
228 that hospitalization blood urea nitrogen (BUN) and D-dimer levels were associated with
229 mortality, and BUN values of ≥ 4.6 mmol/L included a high risk for hospital deaths (14).

230 In another study, 6.29% of COVID-19 patients showed an increase in BUN, and
231 increased basal BUN and creatinine values were reported to cause high mortality (17).

232 Ng et al. (18) reported that being intubated and BUN values are risks for hospital
233 mortality in patients with end-stage renal disease and COVID-19. Although the increase

234 in BUN after SARS-CoV-2 is frequent, the reason for this increase is not clear. Renal
235 epithelial cells contain angiotensin-converting enzyme 2 (ACE2) receptors that are 100

236 times more intense than respiratory epithelial cells; SARS-CoV-2 is internalized to renal
237 cells and may cause renal function loss with cytopathic effect (15, 20). It has been

238 suggested that this may increase the absorption of BUN from the renal tubules by
239 activating the renin-angiotensin-aldosterone system (20). Although IVIG treatment is

240 often used as one of the last treatment options in patients who do not respond to other
241 treatments, IVIG treatment itself may be associated with renal damage (13).

242 On the other hand, the increase in BUN levels in COVID-19 patients may be an
243 indicator of kidney dysfunction and an increased inflammatory state. The renal load

244 caused by increased catabolism, hypovolemia-induced renal hypoperfusion, sepsis,
245 drugs used in the treatment of COVID-19 such as steroid therapy, and rhabdomyolysis

246 may also cause an increase in BUN. Although creatinine, another indicator of renal
247 damage, was not found to be a predictor of mortality in this study, the fact that BUN is
248 predictive of mortality suggests that BUN increases due to inflammatory conditions
249 rather than a renal-induced reason and that increased inflammatory processes play a role
250 in making BUN a risk factor for mortality. Another situation supporting this hypothesis
251 is that inflammatory markers of the patients who died before IVIG treatment were
252 prominently higher and statistically significant than the alive patients. As the most
253 common cause of mortality in COVID-19 is a respiratory failure caused by cytokine
254 storm, the majority of patients (81.5%) in the present study had to be followed up in the
255 intensive care unit due to deterioration in their clinical condition. IVIG treatment is one
256 of the last options in COVID-19 patients who are unresponsive to other therapies and
257 whose cytokine storms are not controlled. It was thought that these patients face an
258 intense inflammatory process, which causes an increase in BUN.

259 The retrospective design, relatively small study population, lack of evaluation of other
260 renal markers such as proteinuria and hematuria, and lack of knowledge of what
261 happened in the post-follow-up period form the main limitations of this study.

262 **5. Conclusion**

263 In conclusion, the study found that urea values before IVIG treatment were a risk factor
264 for mortality in patients who received IVIG treatment for COVID-19. This is important
265 as it indicates that BUN values should be closely monitored in patients given IVIG
266 treatment for COVID-19. It also suggests that when resources are limited and risk
267 stratification is required in COVID-19 patients, BUN values can be helpful.

268

269

270

271

272 **References**

- 273 1. Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics,
274 therapy and vaccination. *Theranostics* 2020; 10(17): 7821-35. 2020/07/21. doi:
275 10.7150/thno.47987.
- 276 2. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a
277 global health crisis. *Physiol Genomics* 2020; 52(11): 549-57. 2020/09/30. doi:
278 10.1152/physiolgenomics.00089.2020.
- 279 3. Ferrer R. [COVID-19 Pandemic: the greatest challenge in the history of critical
280 care]. *Med Intensiva (Engl Ed)* 2020; 44(6): 323-4. 2020/05/08. doi:
281 10.1016/j.medin.2020.04.002.
- 282 4. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery,
283 diagnostics and drug development. *Journal of hepatology* 2021; 74(1): 168-84.
284 2020/10/11. doi: 10.1016/j.jhep.2020.09.031.
- 285 5. Echeverria-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio
286 Cusco M, Ferrandez O, Horcajada JP, et al. Azithromycin in the treatment of COVID-
287 19: a review. *Expert review of anti-infective therapy* 2021; 19(2): 147-63. 2020/08/28.
288 doi: 10.1080/14787210.2020.1813024.
- 289 6. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview.
290 *European journal of pharmacology* 2020; 889: 173644. 2020/10/15. doi:
291 10.1016/j.ejphar.2020.173644.
- 292 7. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2:
293 Structure, Biology, and Structure-Based Therapeutics Development. *Frontiers in*
294 *cellular and infection microbiology* 2020; 10: 587269. 2020/12/17. doi:
295 10.3389/fcimb.2020.587269.
- 296 8. Bakanlık TCS, Müdürlüğü HSG. COVID-19 rehberi antisitokin-anti inflamatu
297 rtedaviler koagulopati yönetimi. 2020, 7 November.
- 298 9. Mazeraud A, Goncalves B, Aegerter P, Mancusi L, Rieu C, Bozza F, et al. Effect
299 of early treatment with polyvalent immunoglobulin on acute respiratory distress
300 syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a
301 randomized controlled trial. *Trials* 2021; 22(1): 170. 2021/03/03. doi: 10.1186/s13063-
302 021-05118-7.
- 303 10. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular
304 intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with
305 COVID-19. *J Infect* 2020; 81(2): 318-56. 2020/04/14. doi: 10.1016/j.jinf.2020.03.044.
- 306 11. Worldometer. COVID-19 CORONAVIRUS PANDEMIC. 2021, March 28.
- 307 12. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute
308 kidney injury in patients hospitalized with COVID-19. *Kidney Int* 2020; 98(1): 209-18.
309 2020/05/18. doi: 10.1016/j.kint.2020.05.006.
- 310 13. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin:
311 adverse effects and safe administration. *Clin Rev Allergy Immunol* 2005; 29(3): 173-84.
312 2006/01/05. doi: 10.1385/CRIAI:29:3:173.

- 313 14. Cheng A, Hu L, Wang Y, Huang L, Zhao L, Zhang C, et al. Diagnostic
314 performance of initial blood urea nitrogen combined with D-dimer levels for predicting
315 in-hospital mortality in COVID-19 patients. *International journal of antimicrobial*
316 *agents* 2020; 56(3): 106110. 2020/07/28. doi: 10.1016/j.ijantimicag.2020.106110.
- 317 15. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is
318 associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; 97(5):
319 829-38. 2020/04/06. doi: 10.1016/j.kint.2020.03.005.
- 320 16. Liu Q, Wang Y, Zhao X, Wang L, Liu F, Wang T, et al. Diagnostic Performance
321 of a Blood Urea Nitrogen to Creatinine Ratio-based Nomogram for Predicting In-
322 hospital Mortality in COVID-19 Patients. *Risk management and healthcare policy* 2021;
323 14: 117-28. 2021/01/21. doi: 10.2147/rmhp.S278365.
- 324 17. Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney Function
325 Indicators Predict Adverse Outcomes of COVID-19. *Med (New York, NY)* 2021; 2(1):
326 38-48.e2. 2020/10/13. doi: 10.1016/j.medj.2020.09.001.
- 327 18. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al.
328 Outcomes of patients with end-stage kidney disease hospitalized with COVID-19.
329 *Kidney Int* 2020; 98(6): 1530-9. 2020/08/19. doi: 10.1016/j.kint.2020.07.030.
- 330 19. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated
331 with severe infection and fatality in patients with COVID-19: A systematic review and
332 meta-analysis of 40 studies and 24,527 patients. *Pharmacological research* 2020; 161:
333 105107. 2020/08/03. doi: 10.1016/j.phrs.2020.105107.
- 334 20. Nogueira SAR, Oliveira SCS, Carvalho AFM, Neves JMC, Silva L, Silva Junior
335 GBD, et al. Renal changes and acute kidney injury in covid-19: a systematic review.
336 *Rev Assoc Med Bras (1992)* 2020; 66Suppl 2(Suppl 2): 112-7. 2020/09/24. doi:
337 10.1590/1806-9282.66.S2.112.

338

339

340

341

342

343

344

345

346

347

348

349

350

351 **Table 1:** Baseline demographic, clinical, and laboratory parameters of the study
 352 population

| Variable | Total (n: 81) | Dead (n:52) | Alive (n: 29) | p |
|----------------------------------|----------------------|--------------------|----------------------|--------------|
| Age | 72 (41-94) | 73.0 (41-94) | 61 (46-78) | 0.391 |
| Gender, F, n (%) | 27 (33.3) | 17 (32.7) | 10 (34.5) | 0.870 |
| Follow up time, day | 19 (1-60) | 20 (1-38) | 16 (3-60) | 0.745 |
| Duration of illness, day | 7 (3-10) | 7 (3-10) | 7 (3-8) | 0.846 |
| Day of stay in hospital | 16 (1-44) | 17 (1-38) | 16 (3-44) | 0.557 |
| Day of stay in inpatient service | 7.90 ±5.98 | 7.15 ±6.03 | 9.24 ±5.75 | 0.133 |
| Day of stay in intensive care | 10 (0-31) | 9.5 (0-31) | 13 (2-21) | 0.509 |
| Intensive care, n (%) | 66 (81.5) | 48 (92.3) | 18 (62.1) | 0.001 |
| Intubation, n (%) | 37 (45.7) | 34 (65.2) | 3 (10.3) | 0.001 |
| Comorbidity | 60 (74.1) | 40 (76.9) | 20 (69.0) | 0.433 |
| Treatment properties | | | | |
| Convalescent plasma, n (%) | 15 (18.5) | 9 (17.3) | 6 (20.7) | 0.707 |
| Pulse steroid therapy, n (%) | 33 (40.7) | 28 (53.8) | 5 (17.2) | 0.001 |
| Tocilizumab treatment, n (%) | 35 (43.2) | 19 (36.5) | 16 (55.2) | 0.105 |
| IVIG treatment, at least | 68 (84) | 42 (80.8) | 26 (89.7) | 0.296 |

| | | | | |
|---|----------------------|----------------------|-------------------------|--------------|
| three days, n (%) | | | | |
| IVIG treatment, in first 24 h, n, % | 50 (61.7) | 30 (57.7) | 20 (69.0) | 0.317 |
| IVIG treatment, in first 48 h, n, % | 52 (64.2) | 32 (61.5) | 20 (69.0) | 0.504 |
| Duration of IVIG treatment, day | 3 (1-5) | 3 (1-5) | 3 (2-5) | 0.069 |
| IVIG dose, gr/day | 40 (25-50) | 40 (25-50) | 50 (30-50) | 0.832 |
| Hematological parameters | | | | |
| WBC count, on hospitalization | 7,960 (1,176-27,350) | 8,185 (1,176-27,350) | 7,349.31 (2,630-20,110) | 0.020 |
| WBC count, before IVIG treatment | 9,570 (430-27,290) | 11,955 (430-27,290) | 8,190 (1,220-25,920) | 0.008 |
| Neutrophil count, on hospitalization, | 7,156.94 ±4,508.17 | 7,716.58 ±4,459.34 | 6,153 ±4,496.95 | 0.136 |
| Neutrophil percentage, on hospitalization | 84.50 (26.10-96.60) | 85.50 (26.10-96.60) | 78.10 (50.20-94.20) | 0.100 |
| Lymphocyte count, on hospitalization | 770 (300-1,777) | 690 (300-1,770) | 780 (600-1,510) | 0.512 |
| Lymphocyte percentage, on hospitalization | 11.30 (2.20-33.10) | 9.30 (2.20-0) | 12 (3-33.10) | 0.081 |
| Lymphocyte count, before IVIG treatment | 520 (130-1,670) | 460 (130-1,490) | 730 (140-1,670) | 0.294 |

| | | | | |
|---|---------------------|---------------------|--------------------|--------------|
| Lymphocyte percentage, before IVIG treatment | 4.30 (0.80-46.50) | 3.35 (0.80-46.50) | 5.60 (2.60-35.70) | 0.001 |
| Platelet count, $\times 10^3$, on hospitalization | 192 (71-442) | 204 (71-372) | 191 (75-422) | 0.030 |
| Platelet count, $\times 10^3$, before IVIG treatment | 244.19 \pm 112.82 | 240.92 \pm 122.01 | 250.04 \pm 95.88 | 0.730 |
| Eosinophil count, on hospitalization | 0 (0-130) | 0 (0-130) | 0 (0-80) | 0.689 |
| Eosinophil percentage, on hospitalization | 0 (0-1.20) | 0 (0-0.90) | 0 (0-1.20) | 0.994 |
| Eosinophil count, before IVIG treatment | 0 (0-180) | 0 (0-180) | 0 (0-120) | 0.077 |
| RDW, on hospitalization | 12.40 \pm 2.58 | 12.32 \pm 2.61 | 12.55 \pm 2.56 | 0.706 |
| RDW, before IVIG treatment | 11.80 (8.40-20.40) | 12.05 (9.40-20.40) | 10.80 (8.40-17.70) | 0.394 |
| Biochemical Parameters | | | | |
| Fasting blood glucose, mg/dL, on hospitalization | 140 (75-480) | 154 (84-361) | 122 (75-480) | 0.034 |
| Fasting blood glucose, before IVIG treatment | 165 (77-344) | 180 (88-344) | 123 (77-263) | 0.195 |
| Urea, on hospitalization | 42 (15-256) | 42.50 (15-256) | 41 (17-180) | 0.863 |

| | | | | |
|-----------------------------------|------------------|------------------|------------------|--------------|
| Urea, before IVIG treatment | 59 (17-230) | 60.50 (33-230) | 43 (17-79.10) | 0.029 |
| Creatine, on hospitalization | 1.03 (0.58-6.87) | 1.04 (0.58-6.87) | 1.02 (0.6-2.20) | 0.629 |
| Creatine, before IVIG treatment | 0.8 (0.5-2.60) | 0.9 (0.52-2.60) | 0.80 (0.50-1.22) | 0.544 |
| LDH, on hospitalization | 457 (188-4,367) | 516 (190-4,367) | 384 (188-1,015) | 0.012 |
| LDH, before IVIG treatment | 570.81 ±213.58 | 597.10 ±201.48 | 524.59 ±229.67 | 0.145 |
| D-dimer, on hospitalization | 0.90 (0.20-5.70) | 0.80 (0.20-5.70) | 0.90 (0.30-2.10) | 0.775 |
| D-dimer, before IVIG treatment | 4.59 ±7.59 | 4.93 ±7.98 | 3.87 ±6.93 | 0.549 |
| Fibrinogen, on hospitalization | 707.47 ±228.52 | 720.08 ±247.29 | 685.39 ±193.60 | 0.525 |
| Fibrinogen, before IVIG treatment | 635.22 ±279.67 | 636.81 ±278.53 | 632.81 ±286.64 | 0.950 |
| Ferritin, on hospitalization | 475.10 (43-4568) | 550 (43-4,568) | 114 (90.2-1,305) | 0.389 |
| Ferritin, before IVIG treatment | 655 (83-3,345) | 699 (83-3,345) | 623 (114-1,659) | 0.613 |
| IgG, on hospitalization | 8.36 ±4.04 | 9.64 ±2.70 | 7.08 ±4.87 | 0.188 |
| IgM, on hospitalization | 0.60 ±0.41 | 0.58 ±0.49 | 0.62 ±0.33 | 0.859 |

| | | | | |
|-----------------------------|-----------------------------|-----------------------------|-------------------------------|--------------|
| IgA, on hospitalization | 2.52 (0.37-7.62) | 2.56 (0.37-7.62) | 2.42 (0.37-7.62) | 0.198 |
| Inflammatory Markers | | | | |
| CRP, on hospitalization | 91.2 (3-415) | 124 (3-415) | 53.70 (8.52-317) | 0.015 |
| CRP, before IVIG treatment | 47.0 (3.10-297) | 82.05 (3.10-297) | 20.80 (3.10-197) | 0.012 |
| SII, on hospitalization | 1834.97 (254.19-12,962.43) | 1953.0 (254.19-11,059.84) | 1064 (352.87-12,962.43) | 0.016 |
| SII, before IVIG treatment | 4,166.94 (657.69-22,356.46) | 5,086.86 (657.69-22,356.46) | 3,753.21 (1,354.69-13,441.37) | 0.013 |
| NLR, on hospitalization | 9.19 (1.86-42.21) | 9.28 (1.93-42.21) | 7.24 (1.86-30.72) | 0.075 |
| NLR, before IVIG treatment | 23.21 (2.33-126.31) | 26.08 (2.33-126.31) | 16.15 (5.80-27.66) | 0.001 |

353 F: Female, IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red
354 cell distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase,
355 AST: Aspartate Aminotransferase, LDH: Lactate dehydrogenase, Ig: Immunoglobulin,
356 CRP: C-reactive protein, SII: Systemic inflammatory index, NLR: Neutrophil
357 lymphocyte ratio

358

359 **Table 2:** Univariate Cox regression analyses demonstrating the relationship between
 360 baseline characteristics and Sars-CoV-2

| Variable | Univariate Analysis | |
|--------------------------------------|-----------------------|--------------|
| | HR (95% CI) | P value |
| Day of stay in inpatient service | 0.951 (0.906 – 0.998) | 0.043 |
| Intubation | 16.370 (4.353-61.565) | 0.001 |
| Intensive care | 0.923 (0.316-0.270) | 0.884 |
| Pulse steroid therapy | 0.910 (0.525 – 1.580) | 0.738 |
| Tocilizumab treatment | 1.436 (0.794 – 2.552) | 0.236 |
| Duration of IVIG treatment, day | 1.419 (0.966 – 2.083) | 0.074 |
| IgG, on hospitalization | 1.234 (0.964 – 1.581) | 0.096 |
| WBC, before IVIG treatment | 1.000 (1.000 – 1.000) | 0.418 |
| Neutrophil count, on hospitalization | 1.000 (1.000 – 1.000) | 0.946 |
| Platelet count, on hospitalization | 1.001 (0.998 – 1.004) | 0.405 |
| Eosinophil count, IVIG öncesi | 0.994 (0.983 – 1.006) | 0.307 |
| FBG, on hospitalization | 1.002 (0.998 – 1.005) | 0.299 |
| FBG, before IVIG treatment | 1.002 (0.999 – 1.006) | 0.192 |
| Urea, before IVIG treatment | 1.011 (1.003 – 1.018) | 0.004 |
| LDH, on hospitalization | 1.000 (0.999 – 1.000) | 0.722 |
| LDH, before IVIG treatment | 1.000 (0.999 – 1.001) | 0.695 |
| IgA, on hospitalization | 1.025 (0.740 – 1.421) | 0.880 |
| CRP, on hospitalization | 1.002 (0.999 – 1.005) | 0.111 |
| CRP, before IVIG treatment | 1.001 (0.998 – 1.005) | 0.364 |

| | | |
|----------------------------|-----------------------|-------|
| SII, on hospitalization | 1.000 (1.000 – 1.000) | 0.746 |
| SII, before IVIG treatment | 1.000 (1.000 – 1.000) | 0.314 |
| NLR, on hospitalization | 1.002 (0.979 – 1.025) | 0.884 |
| NLR, before IVIG treatment | 1.004 (0.994 – 1.014) | 0.414 |

361 Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, F: Female,
 362 IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red cell
 363 distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase, AST:
 364 Aspartate Aminotransferase, FBG: Fasting blood glucose, LDH: Lactate
 365 dehydrogenase, Ig: Immunoglobulin, CRP: C-reactive protein, SII: Systemic
 366 inflammatory index, NLR: Neutrophil lymphocyte ratio

367

368

369

370 **Table 3:** Multivariate Cox regression analyses demonstrating the relationship between
 371 baseline characteristics and Sars-CoV-2

| Variables | Multivariate Analysis | |
|----------------------------------|-----------------------|--------------|
| | HR (95% CI) | P value |
| Intubation | 0.389 (0.218 – 0.693) | 0.001 |
| Day of stay in inpatient service | 0.968 (0.915 – 1.024) | 0.256 |
| Duration of IVIG treatment, day | 0.833 (0.652 – 1.065) | 0.145 |
| Urea, before IVIG treatment | 1.009 (1.002 – 1.017) | 0.009 |

372 Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, IVIG:
 373 Intravenous immunoglobulin

374

375 **Table 4:** Sensitivity and specificity of urea level before IVIG treatment


| Risk factor | AUC (95%) | Cut-off | p | Sensitivity | Specificity |
|-----------------------------|--------------------------|---------|-------|-------------|-------------|
| Urea, before IVIG treatment | 0.647 (0.518 - 0.776) | 60 | 0.029 | 46.2 | 35.5 |

376 AUC: Area under the curve, IVIG: Intravenous immunoglobulin

377

378

379 **Figure 1:** Sensitivity and specificity of urea level before IVIG treatment



Diagonal segments are produced by ties.

380

381